Summary
The use of immunostimulating drugs is one way to intervene in the immune system. Many of these agents are of bacterial origin and most are able to stimulate the nonspecific immune response by acting on polymorphonuclear cells (PMNs) and macrophages. Ribosomal immunotherapy (‘Ribomunyl’) contains both proteoglycans from Klebsiella pneumoniae and ribosomes from 4 different bacterial strains. It can stimulate not only macrophages but also specific antibody production.
‘Ribomunyl’ has been shown to stimulate many of the functions of PMNs, specifically the formation of oxygenated free radicals, Chemotaxis and adhesion. The effect of ‘Ribomunyl’ immunostimulant on the properties of macrophages is of special interest, as these cells participate in both the nonspecific immune response (phagocytosis, proinflammatory cytokine production) and the specific immune response (antigen processing and presentation, lymphocyte proliferation). ‘Ribomunyl’ has been shown to increase the production of many cytokines [interleukin (IL)-1, IL-6, IL-8, tumour necrosis factor-α and colony-stimulating factor], leading to the activation of the cytokine network. ‘Ribomunyl’ was also able to stimulate natural killer cells involved in viral immunity.
Because of the presence of ribosomes from 4 frequently encountered bacterial strains, ‘Ribomunyl’ has specific immunostimulant properties. This has been clearly demonstrated in animals and humans, where specific antibody-forming B cells were found in the tonsils after oral administration. However, specific T-cell response has not been reported, suggesting that ‘Ribomunyl’ could act directly on B cells such as T-cell-independent bacterial antigens.
Similar content being viewed by others
References
Faure G, Béné MC. Use of bacterial ribosomal immunostimulators in respiratory tract infections. Clin Immunother 1995; 4(2): 138–46
Dussourd d’Hinterland L, Normier G, Durand I. Ribosomal vaccines: preparation of subcellular fractions. Arzneimittel Forschung 1980; 30: 126–32
Gregory RL. Microbial ribosomal vaccines. Rev Infect Dis 1986; 8: 208–17
Normier G, Pinel AM, Dussourd d’Hinterland L, et al. Ribosomes as carriers for antigenic determinants of the surface of microorganisms. Dev Biol Stand 1992; 77: 79–85
Hbabi L, Roques C, Michel G, et al. In vitro stimulation of polymorphonuclear cell adhesion by Ribomunyl and antibiotic + Ribomunyl combinations: effects on CD 18, CD35 and CD 16 expression. Int J Immunopharm 1993; 15: 163–73
Pujol JL, Klein B, Godard P, et al. Bacterial ribosomal immunostimulants prime alveolar macrophages in vivo to produce interleukin 1 in vitro. Chest 1991; 100: 644–8
Lini W, De Rossi M, Licciardello L, et al. Chemotactic cytokine gene expression and production induced in human monocytes by membrane proteoglycans from Klebsiella pneumoniae. Int J Immunopharm 1991; 13: 631–7
Allavena P, Erroi A, Pirelli A, et al. Stimulation of cytotoxic and non-cytotoxic functions of natural killer cells by bacterial membrane proteoglycans and ribosomes. Int J Immunopharm 1989; 11: 29–34
Millet J, Lafont S, De Fraissinette A, et al. Polyclonal activation of murine B cells by a membrane proteoglycan of Klebsiella pneumoniae. Clin Exp Immunol 1987; 70: 201–8
Lafont S, Millet I, Kouassi E, et al. Induction of murine B cell proliferation and immunoglobulin synthesis by some bacterial ribosomes. Microbiol Immunol 1988; 32: 1043–58
Fontanges R, Robert D, Content Y, et al. Pouvoir vaccinant de ribosomes extraits de K. pneumoniae, S. pneumoniae, S. pyogenes et H. influenzae et d’une fraction membranaire de K. pneumoniae. Rev Fr Allergol Immunol Clin 1977; 17: 35–81
Ménardo JL, Bousquet J, Clavel R, et al. Immunostimulation à visée respiratoire par un vaccin administré par voie orale. Poumon Coeur 1982; 38(5): 297–300
Faure G, Béné MC, Simon C, et al. Increase in specific antibody-forming cells in human tonsils after oral stimulation with D-53, a ribosomal vaccine. Int J Immunopharm 1990; 12: 315–20
Zanin C, Perrin P, Béné MC, et al. Antibody-producing cells in peripheral blood and tonsils after oral treatment of children with bacterial ribosomes. Int J Immunopharm 1994; 16: 497–505
Hbabi-Haddioui L, Roques C. Inhibition of Streptococcus pneumoniae adhesion by specific salivary IgA after oral immunisation with a ribosomal immunostimulant. Drugs 1997; 54Suppl. 1: 29–32
Millet I, Lafont S, Jeanin M, et al. Proliferative response of human T lymphocyte to a vaccinal preparation of ribosomes from Streptococcus pyogenes. Int Arch Allergy Immunol 1988; 86: 432–5
Snapper CM, Mond JJ. LA model for induction of T-cell-independent humoral immunity in response to polysaccharide antigens. J Immunol 1996; 157: 2229–33
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Clot, J. Pharmacology of Ribosomal Immunotherapy. Drugs 54 (Suppl 1), 33–36 (1997). https://doi.org/10.2165/00003495-199700541-00009
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199700541-00009